Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-269-9 | CAS number: -
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Ames test: non mutagenic (OECD 471, GLP, K, rel. 1).
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 31 July - 15 September 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- GLP study conducted according to OECD Guideline 471 without any deviation
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- dated 21 July 1997
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Version / remarks:
- dated 30 May 2008
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5100 - Bacterial Reverse Mutation Test (August 1998)
- Version / remarks:
- August 1998
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- 28 October 2016
- Type of assay:
- bacterial reverse mutation assay
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Room temperature in the dark
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- The test item was briefly vortexed before being accurately weighed and, on the day of each experiment, approximate half-log dilutions prepared in dimethyl sulphoxide by mixing on a vortex mixer. No correction was required for purity allowance. Prior to use, the solvent was dried to remove water using molecular sieves i.e. 2 mm sodium alumino-silicate pellets with a nominal pore diameter of 4 x 10^-4 microns. All formulations were used within four hours of preparation and were assumed to be stable for this period. - Target gene:
- histidine locus for Salmonella strains and tryptophan for E. coli strain
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not applicable
- Cytokinesis block (if used):
- Not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver homogenate metabolizing system (10% liver S9 in standard co-factors)
- Test concentrations with justification for top dose:
- Experiment 1 - Plate Incorporation Method: 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate, with and without S9-mix
Experiment 2 - Pre-Incubation Method: 5, 15, 50, 150, 500, 1500 and 5000 µg/plate, with and without S9-mix - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: Dimethyl sulphoxide
- Justification for choice of solvent/vehicle: The test item was immiscible in sterile distilled water at 50 mg/mL but was fully miscible in dimethyl sulphoxide at the same concentration in solubility checks performed in-house. Dimethyl sulphoxide was therefore selected as the vehicle. - Untreated negative controls:
- yes
- Remarks:
- untreated
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- 9-aminoacridine
- N-ethyl-N-nitro-N-nitrosoguanidine
- Remarks:
- without metabolic activation
- Untreated negative controls:
- yes
- Remarks:
- untreated
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- other: 2-Aminoanthracene
- Remarks:
- with metabolic activation
- Details on test system and experimental conditions:
- SOURCE OF TEST SYSTEM: The bacteria used in the test were obtained from:
- University of California, Berkeley, on culture discs, on 04 August 1995
- British Industrial Biological Research Association, on a nutrient agar plate, on 17 August 1987
METHOD OF APPLICATION: in agar (plate incorporation) and preincubation
DURATION
- Preincubation period: 20 minutes in Experiment 2.
- Exposure duration: ca. 48 hours
CONTROLS:
- Vehicle/solvent control: Dimethyl sulphoxide; performed in triplicate
- Negative (untreated) controls were performed to assess the spontaneous revertant colony rate; performed in triplicate
- Positive control items used demonstrated a direct and indirect acting mutagenic effect depending on the presence or absence of metabolic activation; performed in triplicate
- Sterility controls were performed in triplicate as follows:
Top agar and histidine/biotin or tryptophan in the absence of S9-mix;
Top agar and histidine/biotin or tryptophan in the presence of S9-mix; and
The maximum dosing solution of the test item in the absence of S9-mix only (test in singular only).
NUMBER OF REPLICATIONS: Triplicate
- OTHER: All of the plates were incubated at 37 ± 3 °C for approximately 48 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity). Several manual counts were required due to revertant colonies spreading slightly, thus distorting the actual plate count. - Rationale for test conditions:
- The dose range for Experiment 1 was predetermined and was 1.5 to 5000 µg/plate (i.e. maximum recommended dose level). The experiment was repeated on a separate day using fresh cultures of the bacterial strains and fresh test item formulations. The dose range was amended, following the results of Experiment 1, and was 5 to 5000 µg/plate. Seven test item dose levels per bacterial strain were selected in the second mutation test in order to achieve both a minimum of four non-toxic dose levels and the potential toxic limit of the test item following the change in test methodology.
- Evaluation criteria:
- Criteria for determining a positive result:
- A dose-related increase in mutant frequency over the dose range tested (De Serres and Shelby, 1979).
- A reproducible increase at one or more concentrations.
- Biological relevance against in-house historical control ranges.
- Fold increase greater than two times the concurrent solvent control for any tester strain (especially if accompanied by an out of historical range response (Cariello and Piegorsch, 1996)).
A test item will be considered non-mutagenic (negative) in the test system if the above criteria are not met.
Although most experiments will give clear positive or negative results, in some instances the data generated will prohibit making a definite judgment about test item activity. Results of this type will be reported as equivocal. - Statistics:
- None
- Key result
- Species / strain:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: A test item film (creamy in appearance) was noted at 5000 μg/plate, this observation did not prevent the scoring of revertant colonies.
MUTAGENICITY
- The vehicle (dimethyl sulphoxide) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
- No visible reduction in the growth of the bacterial background lawn was noted at any dose level, either in the presence or absence of metabolic activation (S9-mix), in Experiment 1 (plate incorporation method) and Experiment 2 (pre-incubation method), although a small reduction in TA100 revertant colony frequency was noted in Experiment 2 at 5000 μg/plate in the absence of S9-mix
- No significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 1 (plate incorporation method) and Experiment 2 (pre incubation method).
- Refer Tables 7.6.1/1 to 7.6.1/5 for more details.
HISTORICAL CONTROL DATA (with ranges, means and standard deviation and confidence interval (e.g. 95%)
- Positive historical control data: Refer Table 7.6.1/6
- Negative (solvent/vehicle) historical control data: Refer Table 7.6.1/6
OTHERS:
- Prior to use, the master strains were checked for characteristics, viability and spontaneous reversion rate (all were found to be satisfactory). The amino acid supplemented top agar and the S9-mix used in both experiments was shown to be sterile. The test item formulation was also shown to be sterile.
- Results for the negative controls (spontaneous mutation rates) are presented in 7.6.1/1 and were considered to be acceptable. These data are for concurrent untreated control plates performed on the same day as the Mutation Test. - Conclusions:
- Under the test conditions, the test item is not considered as mutagenic in Salmonella typhimurium strains TA1535, TA1537, TA98 and TA100, and Escherichia coli strain WP2uvrA.
- Executive summary:
In a reverse gene mutation assay in bacteria, performed according to the OECD Guideline 471 and in compliance with GLP, Salmonella typhimurium strains TA1535, TA1537, TA98 and TA100, and Escherichia coli strain WP2uvrA were exposed to the test item at the following concentrations:
-Experiment 1 - Plate Incorporation Method: 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate, with and without S9-mix
- Experiment 2 - Pre-Incubation Method: 5, 15, 50, 150, 500, 1500 and 5000 µg/plate, with and without S9-mix
Rat liver homogenate (10% liver S9 in standard co-factors) was used as a metabolizing system. Vehicle control, negative (untreated) and positive control groups were also included in mutagenicity tests.
The vehicle (dimethyl sulphoxide) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
In the first experiment (plate incorporation), there was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix).
In the second experiment (pre-incubation), there was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), although a small reduction in TA100 revertant colony frequency was noted at 5000 μg/plate in the absence of S9-mix.
A test item film (creamy in appearance) was noted at 5000 μg/plate, this observation did not prevent the scoring of revertant colonies.
No significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 1 (plate incorporation method) and Experiment 2 (pre incubation method).
Under the test conditions, the test item is not considered as mutagenic in these bacterial systems.
Reference
Table 7.6.1/1: Spontaneous Mutation Rates (Concurrent Negative Controls)
Number of revertants (mean number of colonies per plate) |
|||||||||
Base-pair substitution type |
Frameshift type |
||||||||
Experiment 1 |
|||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||
81 |
|
18 |
|
24 |
|
31 |
|
16 |
|
81 |
(81) |
26 |
(23) |
23 |
(22) |
20 |
(26) |
20 |
(17) |
80 |
|
24 |
|
19 |
|
28 |
|
14 |
|
Experiment 2 |
|||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||
95 |
|
23 |
|
12 |
|
31 |
|
20 |
|
106 |
(95) |
20 |
(22) |
18 |
(16) |
39 |
(34) |
19 |
(19) |
84 |
|
22 |
|
18 |
|
33 |
|
19 |
|
Table 7.6.1/2: Test Results: Experiment 1 – Without Metabolic Activation
Test Period |
From: 05 September 2017 |
To: 08 September 2017 |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
65 85 88 |
(79) 12.5# |
18 25 26 |
(23) 4.4 |
33 32 29 |
(31) 2.1 |
34 39 28 |
(34) 5.5 |
19 21 16 |
(19) 2.5 |
||
1.5 μg |
66 84 68 |
(73) 9.9 |
30 26 34 |
(30) 4.0 |
17 22 28 |
(22) 5.5 |
20 21 14 |
(18) 3.8 |
22 29 15 |
(22) 7.0 |
||
5 μg |
74 87 79 |
(80) 6.6 |
30 18 21 |
(23) 6.2 |
30 31 22 |
(28) 4.9 |
31 38 33 |
(34) 3.6 |
14 17 21 |
(17) 3.5 |
||
15 μg |
86 87 60 |
(78) 15.3 |
23 34 10 |
(22) 12.0 |
28 31 33 |
(31) 2.5 |
23 29 42 |
(31) 9.7 |
13 11 17 |
(14) 3.1 |
||
50 μg |
72 65 83 |
(73) 9.1 |
25 20 21 |
(22) 2.6 |
24 38 40 |
(34) 8.7 |
41 25 21 |
(29) 10.6 |
7 13 19 |
(13) 6.0 |
||
150 μg |
98 89 97 |
(95) 4.9 |
25 30 22 |
(26) 4.0 |
12 34 30 |
(25) 11.7 |
21 21 42 |
(28) 12.1 |
25 17 17 |
(20) 4.6 |
||
500 μg |
78 85 85 |
(83) 4.0 |
19 32 22 |
(24) 6.8 |
33 31 40 |
(35) 4.7 |
23 21 22 |
(22) 1.0 |
15 17 13 |
(15) 2.0 |
||
1500 μg |
86 80 90 |
(85) 5.0 |
25 29 31 |
(28) 3.1 |
32 26 35 |
(31) 4.6 |
33 39 28 |
(33) 5.5 |
15 6 4 |
(8) 5.9 |
||
5000 μg |
77F 76 F 74 F |
(76) 1.5 |
28 F 27 F 31 F |
(29) 2.1 |
34 F 24 F 33 F |
(30) 5.5 |
38 F 38 F 11 F |
(29) 15.6 |
11 F 8 F 3 F |
(7) 4.0 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
||||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
||||||||
631 630 555 |
(605) 43.6 |
742 984 786 |
(837) 128.9 |
720 679 575 |
(658) 74.7 |
235 265 235 |
(245) 17.3 |
187 169 274 |
(210) 56.2 |
|||
ENNG:N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO:4-Nitroquinoline-1-oxide
9AA: 9-Aminoacridine
F: Test ítem film
#: Standard deviation
Table 7.6.1/3: Test Results: Experiment 1 – With Metabolic Activation
Test Period |
From: 05 September 2017 |
To: 08 September 2017 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
90 70 65 |
(75) 13.2# |
17 32 35 |
(28) 9.6 |
25 36 36 |
(32) 6.4 |
38 35 30 |
(34) 4.0 |
16 17 15 |
(16) 1.0 |
||
1.5 µg |
75 68 69 |
(71) 3.8 |
17 23 21 |
(20) 3.1 |
32 42 31 |
(35) 6.1 |
28 25 39 |
(31) 7.4 |
15 14 7 |
(12) 4.4 |
||
5 µg |
79 83 93 |
(85) 7.2 |
25 20 17 |
(21) 4.0 |
34 41 30 |
(35) 5.6 |
34 25 29 |
(29) 4.5 |
13 16 14 |
(14) 1.5 |
||
15 µg |
83 80 83 |
(82) 1.7 |
25 22 20 |
(22) 2.5 |
28 29 23 |
(27) 3.2 |
29 30 22 |
(27) 4.4 |
9 13 21 |
(14) 6.1 |
||
50 µg |
86 70 83 |
(80) 8.5 |
24 33 26 |
(28) 4.7 |
30 38 33 |
(34) 4.0 |
28 31 22 |
(27) 4.6 |
15 18 14 |
(16) 2.1 |
||
150 µg |
87 79 81 |
(82) 4.2 |
28 30 30 |
(29) 1.2 |
37 35 39 |
(37) 2.0 |
30 26 28 |
(28) 2.0 |
10 28 18 |
(19) 9.0 |
||
500 µg |
75 89 69 |
(78) 10.3 |
24 35 38 |
(32) 7.4 |
37 24 22 |
(28) 8.1 |
28 34 27 |
(30) 3.8 |
15 17 14 |
(15) 1.5 |
||
1500 µg |
86 96 74 |
(85) 11.0 |
27 12 17 |
(19) 7.6 |
31 33 36 |
(33) 2.5 |
29 24 25 |
(26) 2.6 |
23 14 16 |
(18) 4.7 |
||
5000 µg |
54 F 48 F 51 F |
(51) 3.0 |
17 F 25 F 23 F |
(22) 4.2 |
11 F 15 F 30 F |
(19) 10.0 |
40 F 26 F 37 F |
(34) 7.4 |
7 F 17 F 5 F |
(10) 6.4 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
1552 1611 1732 |
(1632) 91.8 |
340 289 309 |
(313) 25.7 |
292 266 336 |
(298) 35.4 |
323 255 260 |
(279) 37.9 |
376 392 424 |
(397) 24.4 |
|||
2AA: 2-Aminoanthracene
BP: Benzo(a)pyrene
F: Test ítem film
#: Standard deviation
Table 7.6.1/4: Test Results: Experiment 2 – Without Metabolic Activation
Test Period |
From: 12 September 2017 |
To: 15 September 2017 |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
104 89 79 |
(91) 12.6# |
14 19 16 |
(16) 2.5 |
24 16 17 |
(19) 4.4 |
34 32 28 |
(31) 3.1 |
17 15 13 |
(15) 2.0 |
||
5 μg |
117 90 91 |
(99) 15.3 |
17 16 15 |
(16) 1.0 |
17 29 27 |
(24) 6.4 |
31 30 34 |
(32) 2.1 |
20 19 15 |
(18) 2.6 |
||
15 μg |
86 88 96 |
(90) 5.3 |
16 24 17 |
(19) 4.4 |
15 21 29 |
(22) 7.0 |
31 28 32 |
(30) 2.1 |
22 19 12 |
(18) 5.1 |
||
50 μg |
110 89 100 |
(100) 10.5 |
14 22 20 |
(19) 4.2 |
20 20 14 |
(18) 3.5 |
31 26 32 |
(30) 3.2 |
15 12 13 |
(13) 1.5 |
||
150 μg |
122 78 102 |
(101) 22.0 |
17 14 14 |
(15) 1.7 |
18 15 21 |
(18) 3.0 |
27 29 31 |
(29) 2.0 |
19 8 17 |
(15) 5.9 |
||
500 μg |
106 111 81 |
(99) 16.1 |
22 21 19 |
(21) 1.5 |
20 10 19 |
(16) 5.5 |
29 32 29 |
(30) 1.7 |
6 16 19 |
(14) 6.8 |
||
1500 μg |
92 62 74 |
(76) 15.1 |
17 14 21 |
(17) 3.5 |
17 17 15 |
(16) 1.2 |
25 32 32 |
(30) 4.0 |
14 14 14 |
(14) 0.0 |
||
5000 μg |
35 F 24 F 38 F |
(32) 7.4 |
18 F 13 F 14 F |
(15) 2.6 |
12 F 17 F 16 F |
(15) 2.6 |
21 F 14 F 19 F |
(18) 3.6 |
11 F 9 F 14 F |
(11) 2.5 |
||
Solvent Control (DMSO) |
104 89 79 |
(91) 12.6# |
14 19 16 |
(16) 2.5 |
24 16 17 |
(19) 4.4 |
34 32 28 |
(31) 3.1 |
17 15 13 |
(15) 2.0 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
||||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
||||||||
1366 1248 1449 |
(1354) 101.0 |
527 715 1032 |
(758) 255.2 |
796 828 887 |
(837) 46.2 |
308 302 340 |
(317) 20.4 |
295 237 222 |
(251) 38.6 |
|||
ENNG:N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO:4-Nitroquinoline-1-oxide
9AA: 9-Aminoacridine
F: Test item film
#: Standard deviation
Table 7.6.1/5: Test Results: Experiment 2 – With Metabolic Activation
Test Period |
From: 12 September 2017 |
To: 15 September 2017 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
73 79 84 |
(79) 5.5# |
23 30 26 |
(26) 3.5 |
26 24 22 |
(24) 2.0 |
42 50 46 |
(46) 4.0 |
15 17 16 |
(16) 1.0 |
||
5 μg |
71 76 116 |
(88) 24.7 |
23 28 23 |
(25) 2.9 |
25 21 23 |
(23) 2.0 |
40 41 49 |
(43) 4.9 |
25 19 9 |
(18) 8.1 |
||
15 μg |
86 84 88 |
(86) 2.0 |
28 23 17 |
(23) 5.5 |
17 30 26 |
(24) 6.7 |
44 32 42 |
(39) 6.4 |
18 17 20 |
(18) 1.5 |
||
50 μg |
95 82 93 |
(90) 7.0 |
19 29 24 |
(24) 5.0 |
28 31 22 |
(27) 4.6 |
38 28 30 |
(32) 5.3 |
9 17 12 |
(13) 4.0 |
||
150 μg |
80 74 59 |
(71) 10.8 |
25 22 24 |
(24) 1.5 |
22 22 26 |
(23) 2.3 |
28 33 32 |
(31) 2.6 |
14 10 16 |
(13) 3.1 |
||
500 μg |
78 88 66 |
(77) 11.0 |
26 24 26 |
(25) 1.2 |
34 29 24 |
(29) 5.0 |
36 42 41 |
(40) 3.2 |
14 13 26 |
(18) 7.2 |
||
1500 μg |
84 68 86 |
(79) 9.9 |
28 21 19 |
(23) 4.7 |
32 28 26 |
(29) 3.1 |
28 42 28 |
(33) 8.1 |
14 15 13 |
(14) 1.0 |
||
5000 μg |
67 F 90 F 67 F |
(75) 13.3 |
20 F 14 F 19 F |
(18) 3.2 |
20 F 19 F 17 F |
(19) 1.5 |
31 F 34 F 28 F |
(31) 3.0 |
13 F 17 F 16 F |
(15) 2.1 |
||
Solvent Control (DMSO) |
73 79 84 |
(79) 5.5# |
23 30 26 |
(26) 3.5 |
26 24 22 |
(24) 2.0 |
42 50 46 |
(46) 4.0 |
15 17 16 |
(16) 1.0 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
2373 2589 2649 |
(2537) 145.2 |
314 299 299 |
(304) 8.7 |
416 384 476 |
(425) 46.7 |
233 232 180 |
(215) 30.3 |
488 424 415 |
(442) 39.8 |
|||
2AA: 2-Aminoanthracene
BP: Benzo(a)pyrene
F: Test item film
#: Standard deviation
Table 7.6.1/6:History Profile of Vehicle and Positive Control Values
COMBINED VEHICLE AND UNTREATED CONTROL VALUES 2015 |
|||||||||||||||||||||||||||||||||
Strain S9-Mix |
TA100 |
TA1535 |
TA102 |
WP2uvrA |
TA98 |
TA1537 |
WP2uvrA pKM101 |
WP2pKM101 |
|||||||||||||||||||||||||
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
||||||||||||||||||
Values† |
274 |
278 |
504 |
285 |
26 |
13 |
461 |
229 |
526 |
299 |
506 |
282 |
42 |
51 |
39 |
49 |
|||||||||||||||||
Min |
60 |
61 |
7 |
7 |
222 |
278 |
10 |
12 |
11 |
10 |
4 |
6 |
87 |
98 |
89 |
93 |
|||||||||||||||||
Max |
166 |
175 |
31 |
29 |
376 |
388 |
58 |
43 |
45 |
46 |
27 |
27 |
237 |
254 |
174 |
177 |
|||||||||||||||||
Mean |
91 |
95 |
16 |
14 |
286 |
333 |
24 |
27 |
21 |
24 |
12 |
13 |
156 |
164 |
123 |
137 |
|||||||||||||||||
SD |
19.3 |
19.1 |
4.5 |
4.0 |
48.7 |
37.6 |
5.6 |
5.9 |
6.2 |
6.1 |
3.8 |
3.4 |
42.2 |
35.6 |
23.1 |
21.2 |
|||||||||||||||||
POSITIVE CONTROL VALUES 2015 |
|
||||||||||||||||||||||||||||||||
Strain S9-Mix |
TA100 |
TA1535 |
TA102 |
WP2uvrA |
TA98 |
TA1537 |
WP2uvrA pKM101 |
WP2pKM101 |
|
||||||||||||||||||||||||
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
|
|||||||||||||||||
Values |
276 |
280 |
252 |
264 |
13 |
13 |
231 |
227 |
262 |
276 |
253 |
261 |
20 |
35 |
20 |
35 |
|
||||||||||||||||
Min |
222 |
250 |
79 |
118 |
953 |
673 |
116 |
103 |
100 |
78 |
164 |
97 |
430 |
494 |
745 |
325 |
|
||||||||||||||||
Max |
2266 |
2402 |
2779 |
457 |
3140 |
1655 |
2769 |
550 |
502 |
705 |
2318 |
823 |
1696 |
2264 |
3662 |
1174 |
|
||||||||||||||||
Mean |
614 |
927 |
472 |
246 |
2303 |
1093 |
792 |
266 |
222 |
218 |
911 |
336 |
761 |
1461 |
2257 |
569 |
|
||||||||||||||||
SD |
260.6 |
452.5 |
434.8 |
55.7 |
815.2 |
376.5 |
342.1 |
97.7 |
70.2 |
107.6 |
412.4 |
135.7 |
350.0 |
382.0 |
790.7 |
220.3 |
|
||||||||||||||||
COMBINED VEHICLE AND UNTREATED CONTROL VALUES 2016 |
|||||||||||||||||||||||||||||||||
Strain S9-Mix |
TA100 |
TA1535 |
TA102 |
WP2uvrA |
TA98 |
TA1537 |
WP2uvrA pKM101 |
WP2pKM101 |
|||||||||||||||||||||||||
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
||||||||||||||||||
Values |
399 |
401 |
758 |
393 |
60 |
30 |
690 |
345 |
788 |
415 |
762 |
398 |
32 |
32 |
16 |
24 |
|||||||||||||||||
Min |
63 |
66 |
8 |
8 |
216 |
221 |
10 |
13 |
8 |
12 |
3 |
4 |
97 |
104 |
78 |
52 |
|||||||||||||||||
Max |
154 |
156 |
34 |
39 |
340 |
375 |
53 |
53 |
49 |
51 |
24 |
23 |
268 |
243 |
148 |
166 |
|||||||||||||||||
Mean |
90 |
93 |
15 |
15 |
268 |
310 |
22 |
27 |
21 |
25 |
12 |
13 |
161 |
159 |
118 |
110 |
|||||||||||||||||
SD |
14.5 |
14.3 |
4.5 |
5.2 |
26.4 |
31.1 |
5.8 |
6.3 |
4.8 |
5.7 |
3.5 |
3.5 |
39.2 |
32.3 |
17.0 |
29.3 |
|||||||||||||||||
POSITIVE CONTROL VALUES 2016 |
|
||||||||||||||||||||||||||||||||
Strain S9-Mix |
TA100 |
TA1535 |
TA102 |
WP2uvrA |
TA98 |
TA1537 |
WP2uvrA pKM101 |
WP2pKM101 |
|
||||||||||||||||||||||||
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
|
|||||||||||||||||
Values |
409 |
406 |
381 |
386 |
30 |
28 |
341 |
335 |
388 |
385 |
379 |
381 |
14 |
24 |
8 |
16 |
|
||||||||||||||||
Min |
221 |
284 |
84 |
92 |
897 |
629 |
107 |
102 |
100 |
96 |
95 |
101 |
445 |
574 |
1674 |
372 |
|
||||||||||||||||
Max |
2222 |
2863 |
2994 |
879 |
2326 |
2140 |
1611 |
637 |
449 |
4357 |
1413 |
639 |
1117 |
1855 |
2823 |
945 |
|
||||||||||||||||
Mean |
724 |
1264 |
854 |
240 |
1633 |
950 |
718 |
240 |
186 |
188 |
406 |
290 |
743 |
1271 |
2379 |
535 |
|
||||||||||||||||
SD |
320.4 |
562.9 |
664.9 |
62.1 |
564.5 |
382.7 |
338.6 |
98.2 |
49.8 |
230.8 |
227.0 |
92.7 |
214.6 |
326.5 |
426.2 |
143.3 |
|
||||||||||||||||
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Table 7.6/1: Summary of genotoxicity test
Test n° |
Test / Guideline Reliability |
Focus |
Strains tested |
Metabolic activation |
Test concentration |
Statement |
1
Thompson, 2017 |
Ames Test (OECD 471) K, rel. 1 |
Gene mutation |
TA 1535, TA 1537, TA 98, TA 100, WP2 uvrA |
-S9 +S9 |
Up to cytotoxic or highest recommended concentration |
-S9 : non mutagenic +S9 : non mutagenic |
Justification for classification or non-classification
Harmonized classification:
The registered substance has no harmonized classification according to the Regulation (EC) No. 1272/2008.
Self-classification:
Based on the available information, no classification is proposed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
